Literature DB >> 34983707

Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2.

Eli Magen1, Avi Yakov1, Ilan Green1, Ariel Israel1, Shlomo Vinker1, Eugene Merzon1.   

Abstract

Background: The factors that trigger and exacerbate chronic spontaneous urticaria (CSU) are well known, but it is not unclear whether messenger RNA (mRNA) vaccination against severe acute respiratory syndrome coronavirus 2 can trigger new cases of CSU or a relapse of CSU after long-term remission. Objective: To study the clinical cases of patients with new-onset CSU and CSU in remission who relapsed within 3 months after BNT162b2 mRNA vaccination.
Methods: All patients with a CSU diagnosis within 12 weeks of BNT162b2 mRNA vaccination were retrospectively identified and included in the new-onset CSU and the relapsed CSU groups. The first control group (CSU control group) retrospectively consisted of patients diagnosed with CSU in complete clinical remission for ≥ 6 months, with no CSU relapse after vaccination. The second control group (healthy control group) consisted of subjects who were fully vaccinated and without CSU, matched 1:2 for age and sex with patients with CSU.
Results: Twenty-seven patients were included in the relapsed CSU group, 32 patients in the new-onset CSU group, 179 patients in the CSU control group, and 476 subjects in the healthy control group. The relapsed CSU and new-onset CSU groups had more allergic comorbidities overall (19 [70.4%] and 13 [40.6%], respectively) than the CSU control group and the healthy control group (50 [27.9%] and 110 [23.1%], respectively; p < 0.001). Multiple logistic regression analysis showed that a positive autologous serum skin test result, overall allergic comorbidities, and basopenia were positively associated with the probability of CSU relapse within 3 months after BNT162b2 mRNA vaccination (odds ratio [OR] 5.54 [95% confidence interval {CI}, 2.36-13.02], p < 0.001); OR 6.13 [95% CI, 2.52-14.89], p = 0.001; and OR 2.81 [95% CI, 1.17-6.72, p = 0.020, respectively).
Conclusion: It is possible that BNT162b2 mRNA vaccination serves as a provoking and/or relapsing factor of CSU in individuals with allergic diseases and/or predisposed autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34983707      PMCID: PMC8749250          DOI: 10.2500/aap.2022.43.210111

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  37 in total

1.  The COVID vaccine challenges that lie ahead.

Authors: 
Journal:  Nature       Date:  2020-11       Impact factor: 49.962

2.  The global impact of the COVID-19 pandemic on the management and course of chronic urticaria.

Authors:  Emek Kocatürk; Andaç Salman; Ivan Cherrez-Ojeda; Paulo Ricardo Criado; Jonny Peter; Elif Comert-Ozer; Mohamed Abuzakouk; Rosana Câmara Agondi; Mona Al-Ahmad; Sabine Altrichter; Rand Arnaout; Luisa Karla Arruda; Riccardo Asero; Andrea Bauer; Moshe Ben-Shoshan; Jonathan A Bernstein; Mojca Bizjak; Isabelle Boccon-Gibod; Hanna Bonnekoh; Laurence Bouillet; Zenon Brzoza; Paula Busse; Regis A Campos; Emily Carne; Niall Conlon; Roberta F Criado; Eduardo M de Souza Lima; Semra Demir; Joachim Dissemond; Sibel Doğan Günaydın; Irina Dorofeeva; Luis Felipe Ensina; Ragıp Ertaş; Silvia Mariel Ferrucci; Ignasi Figueras-Nart; Daria Fomina; Sylvie M Franken; Atsushi Fukunaga; Ana M Giménez-Arnau; Kiran Godse; Margarida Gonçalo; Maia Gotua; Clive Grattan; Carole Guillet; Naoko Inomata; Thilo Jakob; Gul Karakaya; Alicja Kasperska-Zając; Constance H Katelaris; Mitja Košnik; Dorota Krasowska; Kanokvalai Kulthanan; M Sendhil Kumaran; Claudia Lang; José Ignacio Larco-Sousa; Elisavet Lazaridou; Tabi Anika Leslie; Undine Lippert; Oscar Calderón Llosa; Michael Makris; Alexander Marsland; Iris V Medina; Raisa Meshkova; Esther Bastos Palitot; Claudio A S Parisi; Julia Pickert; German D Ramon; Mónica Rodríguez-Gonzalez; Nelson Rosario; Michael Rudenko; Krzysztof Rutkowski; Jorge Sánchez; Sibylle Schliemann; Bulent Enis Sekerel; Faradiba S Serpa; Esther Serra-Baldrich; Zhiqiang Song; Angèle Soria; Maria Staevska; Petra Staubach; Anna Tagka; Shunsuke Takahagi; Simon Francis Thomsen; Regina Treudler; Zahava Vadasz; Solange Oliveira Rodrigues Valle; Martijn B A Van Doorn; Christian Vestergaard; Nicola Wagner; Dahu Wang; Liangchun Wang; Bettina Wedi; Paraskevi Xepapadaki; Esra Yücel; Anna Zalewska-Janowska; Zuotao Zhao; Torsten Zuberbier; Marcus Maurer
Journal:  Allergy       Date:  2020-12-07       Impact factor: 13.146

3.  The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria.

Authors:  R A Sabroe; C E Grattan; D M Francis; R M Barr; A Kobza Black; M W Greaves
Journal:  Br J Dermatol       Date:  1999-03       Impact factor: 9.302

Review 4.  Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives.

Authors:  Vanitha Sampath; Grace Rabinowitz; Mihir Shah; Surabhi Jain; Zuzana Diamant; Milos Jesenak; Ronald Rabin; Stefan Vieths; Ioana Agache; Mübeccel Akdis; Domingo Barber; Heimo Breiteneder; Sharon Chinthrajah; Tomas Chivato; William Collins; Thomas Eiwegger; Katharine Fast; Wytske Fokkens; Robyn E O'Hehir; Markus Ollert; Liam O'Mahony; Oscar Palomares; Oliver Pfaar; Carmen Riggioni; Mohamed H Shamji; Milena Sokolowska; Maria Jose Torres; Claudia Traidl-Hoffmann; Menno van Zelm; De Yun Wang; Luo Zhang; Cezmi A Akdis; Kari C Nadeau
Journal:  Allergy       Date:  2021-06-04       Impact factor: 13.146

5.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Authors:  Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks
Journal:  N Engl J Med       Date:  2020-12-30       Impact factor: 91.245

6.  Autoimmune Chronic Spontaneous Urticaria Detection with IgG Anti-TPO and Total IgE.

Authors:  Pavel Kolkhir; Elena Kovalkova; Anton Chernov; Inna Danilycheva; Karoline Krause; Merle Sauer; Andrey Shulzhenko; Daria Fomina; Marcus Maurer
Journal:  J Allergy Clin Immunol Pract       Date:  2021-08-04

7.  Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine.

Authors:  Tom Shimabukuro; Narayan Nair
Journal:  JAMA       Date:  2021-02-23       Impact factor: 56.272

8.  COVID-19 Vaccination-Induced Rash: Does the Choice of Vaccine Matter?

Authors:  Mansoor Zafar; Baby Ewnetu; Saif Ahmed; Uzair Iqbal; Mark Whitehead
Journal:  Cureus       Date:  2021-06-07

9.  SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.

Authors:  Kizzmekia S Corbett; Darin K Edwards; Sarah R Leist; Olubukola M Abiona; Seyhan Boyoglu-Barnum; Rebecca A Gillespie; Sunny Himansu; Alexandra Schäfer; Cynthia T Ziwawo; Anthony T DiPiazza; Kenneth H Dinnon; Sayda M Elbashir; Christine A Shaw; Angela Woods; Ethan J Fritch; David R Martinez; Kevin W Bock; Mahnaz Minai; Bianca M Nagata; Geoffrey B Hutchinson; Kai Wu; Carole Henry; Kapil Bahl; Dario Garcia-Dominguez; LingZhi Ma; Isabella Renzi; Wing-Pui Kong; Stephen D Schmidt; Lingshu Wang; Yi Zhang; Emily Phung; Lauren A Chang; Rebecca J Loomis; Nedim Emil Altaras; Elisabeth Narayanan; Mihir Metkar; Vlad Presnyak; Cuiping Liu; Mark K Louder; Wei Shi; Kwanyee Leung; Eun Sung Yang; Ande West; Kendra L Gully; Laura J Stevens; Nianshuang Wang; Daniel Wrapp; Nicole A Doria-Rose; Guillaume Stewart-Jones; Hamilton Bennett; Gabriela S Alvarado; Martha C Nason; Tracy J Ruckwardt; Jason S McLellan; Mark R Denison; James D Chappell; Ian N Moore; Kaitlyn M Morabito; John R Mascola; Ralph S Baric; Andrea Carfi; Barney S Graham
Journal:  Nature       Date:  2020-08-05       Impact factor: 49.962

View more
  6 in total

1.  Evaluation and management of adverse reactions to the COVID-2019 vaccines.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2022-01-01       Impact factor: 2.587

2.  Eosinophilic esophagitis: from discovery to effective treatment.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2022-05-01       Impact factor: 2.873

3.  Chronic spontaneous urticaria after COVID-19 primary vaccine series and boosters.

Authors:  Alexis Strahan; Rowanne Ali; Esther E Freeman
Journal:  JAAD Case Rep       Date:  2022-05-26

4.  Chronic spontaneous urticaria following COVID-19 vaccination.

Authors:  Laurence de Montjoye; Anne Herman; Marie Baeck
Journal:  JAAD Case Rep       Date:  2022-05-21

5.  Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database.

Authors:  Julianne M Falotico; Amar D Desai; Asghar Shah; Jose W Ricardo; Shari R Lipner
Journal:  Am J Clin Dermatol       Date:  2022-08-05       Impact factor: 6.233

6.  Clinical and immunological data from chronic urticaria onset after mRNA SARS-CoV-2 vaccines.

Authors:  Eva Pescosolido; Yannick D Muller; Marina Sabaté-Brescó; Marta Ferrer; Daniel Yerly; Jean-Christoph Caubet; Jean-Pierre Lantin; Camillo Ribi; Marcel M Bergmann
Journal:  Clin Exp Allergy       Date:  2022-08-13       Impact factor: 5.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.